Patient leaflet in accordance with the
Pharmacists' Regulations (Preparations) - 1986
The medicine is dispensed with a doctor's prescription only

NUBEQA 300 mg
Film-coated tablets

Active ingredient
Each tablet of NUBEQA contains: darolutamide 300 mg.
Inactive ingredients and allergens in this medicine: See section 2 under 'Important information about some of this medicine's ingredients', and section 6 'Additional information'.
Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours.

1. What is this medicine intended for?

NUBEQA in combination with androgen deprivation therapy (ADT) is intended to treat **adult men who have** castration resistant **prostate cancer** with no metastases and who are at high risk of developing a metastatic disease.

NUBEQA in combination with docetaxel is intended to treat **adult men with prostate cancer** that has spread to other parts of the body and responds to medical or surgical treatment that lowers testosterone.

Mechanism of action:
NUBEQA blocks the activity of the male sex hormones called androgens, such as testosterone.
By blocking these hormones, darolutamide stops prostate cancer cells from growing and dividing.

Therapeutic group: endocrine therapy, anti-androgen

2. Before using this medicine

Do not use this medicine if:

- you are sensitive (allergic) to the active ingredient darolutamide or to any of the other ingredients in this medicine. For a list of the inactive ingredients, see section 6 'Additional information'.
- you are a woman who is or may become pregnant.

Special warnings about using this medicine
Before using NUBEQA, tell your doctor if:

- you have problems with your kidneys
- you have problems with your liver
- you have any heart condition, including heart rhythm problems or if you are using medicines for these conditions

- you have had a surgery to treat blood vessel problems.
Taking NUBEQA may affect your liver function tests. If your blood tests show abnormal results of your liver function, your doctor may decide to stop treatment permanently.

Children and adolescents
This medicine is not intended for use in children and adolescents under 18 years old. There is no relevant use of NUBEQA in children and adolescents.

Other medicines and NUBEQA
If you are taking or have recently taken other medicines, including nonprescription medications and dietary supplements, tell your doctor or pharmacist.

The following medicines may influence the effect of NUBEQA, or NUBEQA may influence the effect of these medicines that are intended to treat:

- bacterial infections, such as **rifampicin**
- fungal infections, such as **itraconazole**
- sedation and sleeping - **midazolam**
- epilepsy, such as **carbamazepine, phenobarbital, phenytoin**
- symptoms of slightly low mood and mild anxiety: **Hypericum** (**St. John's wort** an herbal medicine)
- high cholesterol, such as **rosuvastatin, fluvastatin, atorvastatin, pitavastatin**
- severe joint inflammation, severe cases of the skin disease psoriasis, and cancers: **methotrexate**
- inflammatory bowel diseases: **sulfasalazine**

Your doctor may change the dose of the medicines that you are taking.

Using this medicine and food
Take this medicine with food.

Pregnancy, breastfeeding, and fertility
NUBEQA is not intended for use in women.
This medicine may affect male fertility.

Darolutamide can harm the development of the unborn baby.

Follow these guidelines:
- If your partner can become pregnant, use a highly effective method of contraception to prevent pregnancy while taking NUBEQA and for up to one week after stopping treatment with NUBEQA.
- If your partner is pregnant, use a condom to protect the unborn baby during treatment and for one week after stopping treatment with NUBEQA.

Driving and using machines
This medicine is unlikely to affect your ability to drive and use machines.

- **Important information about some of this medicine's ingredients**
  NUBEQA contains lactose (a type of sugar).

If you have an intolerance to any sugars, consult your doctor before taking this medicine.

3. How to use this medicine?

Always use this medicine according to your doctor's instructions.
Check with your doctor or pharmacist if you are not sure about your dose or about how to take this medicine.
Only your doctor will determine your dose and how you should take this medicine.
The recommended dosage is: 2 tablets twice a day.
Your doctor may reduce your dose to one tablet twice a day, if you have problems with your liver or kidneys.

Do not exceed the recommended dose.

Method of use:
Swallow the tablets whole; take them with food and a glass of water.
There is no information about splitting, crushing, or chewing.
Your doctor will prescribe additional medicines while you are taking NUBEQA.

If you have accidentally taken a higher dose, contact your doctor immediately. At the same time, continue the treatment as usual and take your next dose at the usual time.
If a child has accidentally swallowed some medicine, immediately see a doctor or go to a hospital emergency room and bring the medicine package with you.

If you forget to take the medicine
If you forget to take the medicine at the scheduled time, take your missed dose as soon as you remember before the next dose.
Do not take a double dose to make up for one or more forgotten tablets. Adhere to the treatment as recommended by your doctor.

If you stop taking this medicine
Do not stop taking this medicine without explicit instruction from your doctor.

Do not take medicines in the dark! Check the label and dose every time you take medicine. Wear glasses if you need them.

If you have any further questions about using this medicine, consult your doctor or pharmacist.

4. Side effects

As with any medicine, using NUBEQA may cause side effects in some users. Do not be alarmed by this list of side effects; you may not experience any of them.

NUBEQA side effects occur with the following frequencies:

In patients with non-metastatic castration-resistant prostate cancer

Very common side effects (may affect more than 1 in 10 users)
- Tiredness
    - blood tests showing reduced number of a white blood cell type called neutrophils
    - blood tests showing increased levels of substances produced by the liver: bilirubin, aspartate transaminase

Common side effects (may affect up to 1 in 10 users)
- blockage of the arteries in the heart
- heart failure
- rash
- pain in arms and legs
- pain in muscles and bones
- broken bones

In patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Very common side effects (may affect more than 1 in 10 users)
- high blood pressure
- rash
- blood tests showing a reduced number of the white blood cells called neutrophils
- blood tests showing increased levels of substances produced by the liver: bilirubin, alanine transaminase and aspartate transaminase

Common side effects (may affect up to 1 in 10 users)
- broken bones
- breast enlargement in men

If you experience any side effect, if any side effect gets worse, or if you experience a side effect not mentioned in this leaflet, consult your doctor.

Reporting side effects
You can report side effects to the Ministry of Health by following the 'Reporting Side Effects of Drug Treatment' link on the Ministry of Health home page (www.health.gov.il), which opens an online form for reporting side effects, or you can also use this link: https://sideeffects.health.gov.il

5. How to store the medicine?

- Prevent poisoning! To prevent poisoning, keep this and all other medicines in a closed place, out of the reach and sight of children and/or infants. Do not induce vomiting unless explicitly instructed to do so by your doctor.
- Do not use the medicine after the expiry date (exp. date) which is stated on the package. The expiry date refers to the last day of that month.
- This medicine does not require any special storage conditions. Keeping it at room temperature is recommended.
- Do not throw away any medicine via wastewater or household waste. Ask the pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

6. Additional information

In addition to the active ingredient, this medicine also contains:

lactose monohydrate, calcium hydrogen phosphate (E 341), croscarmellose sodium, povidone K 30 (E 1201), hypromellose 15cP, magnesium stearate (E 470b), macrogol 3350 (E 1521), titanium dioxide (E 171).

Each tablet contains 186.16 mg lactose monohydrate, see section 2 'Before using this medicine'.

What the medicine looks like and contents of the pack:
Film-coated, white to off-white, oval tablet marked '300' on one side and 'BAYER' on the other.
The pack contains 7 blisters; each blister contains 16 tablets (total of 112 tablets per pack).

- **Registration holder's name and address:** Bayer Israel Ltd., 36 Hacharash St., Hod Hasharon 4527702.
- **Manufacturer's name and address:** Orion Corporation, Orion Pharma, Salo, Joensuunkatu 7, 24100 Salo, Finland.
- Approved in July 2023.
- Registration number of the medicine in the Ministry of Health's National Drug Registry: 167-12-36564-99